KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Change in Inventory: 2020-2025

Historic Change in Inventory for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to -$5.9 million.

  • Esperion Therapeutics' Change in Inventory fell 35.72% to -$5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.4 million, marking a year-over-year decrease of 0.80%. This contributed to the annual value of $28.9 million for FY2024, which is 5.11% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Change in Inventory of -$5.9 million as of Q3 2025, which was down 139.14% from $15.1 million recorded in Q2 2025.
  • Esperion Therapeutics' Change in Inventory's 5-year high stood at $15.1 million during Q2 2025, with a 5-year trough of -$6.4 million in Q2 2022.
  • Over the past 3 years, Esperion Therapeutics' median Change in Inventory value was $6.3 million (recorded in 2023), while the average stood at $6.7 million.
  • In the last 5 years, Esperion Therapeutics' Change in Inventory crashed by 274.32% in 2022 and then surged by 1,739.94% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Change in Inventory (Quarterly) stood at $422,000 in 2021, then surged by 1,240.28% to $5.7 million in 2022, then surged by 150.85% to $14.2 million in 2023, then increased by 1.42% to $14.4 million in 2024, then slumped by 35.72% to -$5.9 million in 2025.
  • Its Change in Inventory stands at -$5.9 million for Q3 2025, versus $15.1 million for Q2 2025 and $4.8 million for Q1 2025.